• View the talks
• 36 min
  1. Streptococcus pneumoniae: serotype diversity and epidemiology

  • Dr. Bambos Charalambous
• 38 min
  2. Tuberculosis: new treatments in evolution

  • Prof. Stephen Gillespie
• 55 min
  3. Current drugs for TB treatment

  • Dr. Kasha Singh
• 41 min
  4. Global progress in TB vaccine development

  • Prof. Helen McShane
• 34 min
  5. Management of MDR and XDR TB

  • Prof. Martin Boeree
• 61 min
  6. Non-tuberculous mycobacterial pulmonary disease (NTM-PD)

  • Prof. Jakko van Ingen
• 51 min
  7. The making of an influenza pandemic

  • Prof. Jonathan Van-Tam
• 51 min
  8. Responding to pandemic influenza

  • Prof. Jonathan Van-Tam
  • Dr. Chloe Sellwood
• 38 min
  9. Controlling pandemic flu

  • Prof. John Oxford
• 30 min
  10. The future of influenza vaccines

  • Dr. Marc P. Girard
• 29 min
  11. Emerging or newly discovered viral causes of acute lower respiratory tract infections worldwide

  • Dr. Marietjie Venter
  • Mrs. Orienka Hellferscee
• 29 min
  12. Respiratory syncytial virus vaccination

  • Prof. Peter Openshaw
• 34 min
  13. RSV vaccine development

  • Prof. Ruth Karron
• 32 min
  14. Respiratory mycoplasmas

  • Prof. Stephen Gillespie
• 52 min
  15. Infection in the cystic fibrosis lung

  • Dr. Stuart Elborn
• 34 min
  16. The role of infection at COPD exacerbations

  • Prof. Wisia Wedzicha
• 58 min
  17. An overview of non-cystic fibrosis bronchiectasis

  • Dr. Maeve P. Smith
• 27 min
  18. Legionella: epidemiology and human infection, environment and diagnosis

  • Dr. Diane Lindsay
• 24 min
  19. Pathogen discovery in the respiratory tract

  • Dr. H. Rogier van Doorn
• 38 min
  20. Aspergillosis infections and the lung

  • Prof. Rosemary Barnes
• 23 min
  21. Parasitic lung infections: protozoa, cestodes & trematodes

  • Dr. Vannan Kandi Vijayan
• 16 min
  22. Parasitic lung infections: nematodes

  • Dr. Vannan Kandi Vijayan
• 37 min
  23. Improving respiratory diagnostics (viruses)

  • Prof. David Murdoch

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. RSV vaccine development
3. Financial disclosures
4. Respiratory syncytial virus (RSV)
5. RSV structure
6. RSV seasonality
7. RSV is a global pediatric pathogen
8. The spectrum of RSV illness in young children
9. Risk factors for severe RSV disease
10. Pediatric RSV hospitalizations distribution
11. RSV also causes illness in the elderly
12. Goal for RSV vaccines (1)
13. RSV can reinfect healthy young adults
14. Goal for RSV vaccines (2)
15. Vaccine for RSV does not yet exist
16. Obstacles to RSV vaccine development
17. Peak of severe RSV disease
18. Heterogeneous at-risk population (young and old)
19. Enhanced RSV disease
20. The formalin inactivated RSV vaccine study results
21. What do we know about enhanced RSV disease?
22. Mechanisms of disease enhancement: humoral
23. Mechanisms of disease enhancement: cellular
24. Implications for RSV vaccine development
25. Prophylaxis against RSV disease
26. Passive prophylaxis
27. Use of palivizumab
28. Passive prophylaxis do not replace vaccination
29. Active prophylaxis: RSV vaccines
30. Subunit RSV vaccines
31. RSV F is the primary target for subunit vaccines
32. Potential target populations for RSV F vaccine
33. RSV F structure and vaccine development
34. Novartis postfusion RSV F vaccine
35. RSV F nanoparticle vaccine
36. More approaches to RSV vaccine development
37. Summary: RSV F subunit vaccines
38. Live RSV vaccines (1)
39. Live RSV vaccines: advantages and limitations
40. Live RSV vaccines (2)
41. Live attenuated (native) RSV vaccines
42. Attenuating mutations in rA2cp248/404/1030/ΔSH
43. Clinical experience with rA2cp248/404/1030/ΔSH
44. Current status of rA2cp248/404/1030/ΔSH
45. RSV MEDI ΔM2-2: a novel rRSV deletion mutant
46. Summary: live-attenuated rRSV vaccines
47. Vectored RSV vaccines
48. Potential advantages of vectored RSV vaccines
49. MEDI-534: a chimeric rB/HPIV3/RSV F vaccine
50. MEDI-534: antibody responses
51. Sendai-vectored RSV vaccine (rSV-RSV-F)
52. Replication-defective vectors
53. Other novel technologies
54. RSV vaccines: what will the next decade bring?
55. Our goal: to protect infants and children from RSV

Topics Covered

• Many obstacles hinder RSV vaccine development
• Disease at extremes of age
• History of disease potentiation with formalin-inactivated RSV vaccine
• Various strategies for vaccine development
• RSV F subunit vaccine
• Maternal immunization
• Immunization of the elderly
• Live-attenuated and/or live-vectored vaccines
• Immunization of infants and children

Links

Series:

• Respiratory Infection

Categories:

• Immunology
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases
• Vaccines

Talk Citation

Publication History

• Published on July 11, 2013

Financial Disclosures

• Prof. Ruth Karron has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.